Bavarian Nordic A/S (BAVA.VI)
Vienna · EUR · Healthcare · Biotechnology
€34.02 (+2.90%) as of
Key statistics
- Market cap
- 2.54B
- P/E (TTM)
- 13.03
- EPS (TTM)
- 2.61
- Dividend yield
- 0.00%
- 52-week range
- 22.96 – 34.02
- Beta
- 0.98
- Revenue (TTM)
- 6.34B
- Profit margin
- 24.34%
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hellerup, Denmark
- Employees
- 1,906
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.